Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19
Open accessPublished version of a preprint
Abstract
Summary: Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Therapy for cytokine release syndrome and its neurological toxicity chiefly targets IL-6, which probably originates from monocytes or activated endothelial cells.
“Treatment for CRS and associated neurotoxicity primarily targets IL-6, likely arising from monocytes or activated endothelium [1, 6, 11–17].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [16]
The section on cytokine release in SARS-CoV-2 infection says IL-6 signaling is central to CAR T-cell–associated CRS and that IL-6 or IL-6R blockade can prevent life-threatening complications. The figure caption in the Conclusion attributes IL-6 secretion to macrophages. Our copy does not address treatment of associated neurotoxicity or identify activated endothelial cells as an IL-6 source; page numbers are unavailable. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445 · see citing works
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 12× · see citing works
“Thus, JAK inhibitors can lessen inflammation caused due to CRS. JAK inhibitors such as tofacitinib and baricitinib are safe and can establish plasma concentration of inhibition, but their efficacy in treating patients with COVID-19 remains to be determined (14).”
BackgroundInfluentialTian, S., Hu, W., Niu, L., Liu, H., Xu, H., & Xiao, S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.010 · Cited by 1,414 · see citing works
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270 · see citing works
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266 · see citing works
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102 · see citing works
Self-citationTargeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 870 · see citing works
C-reactive protein levels in the early stage of COVID-19
Wang, L. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.007 · Cited by 684 · see citing works
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604 · see citing works
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 401 · see citing works
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331 · see citing works
Covid-19 — The Search for Effective Therapy
Baden, L. R., & Rubin, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejme2005477 · Cited by 324 · see citing works
Das, R., Guan, P. F., Sprague, L., Verbist, K., Tedrick, P., An, Q., Cheng, C., Kurachi, M., Levine, R. L., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254 · see citing works
LY6E impairs coronavirus fusion and confers immune control of viral disease
Pfaender, S., Mar, K. B., Michailidis, E., Kratzel, A., Boys, I. N., V’kovski, P., Fan, W., Kelly, J. N., Hirt, D., Ebert, N., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0769-y · Cited by 214 · see citing works
Schulert, G. S., Zhang, M., Fall, N., Husami, A., Kissell, D., Hanosh, A., Zhang, K., Davis, K., Jentzen, J. M., Napolitano, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv550 · Cited by 170 · see citing works
Suppression of Coronavirus Replication by Cyclophilin Inhibitors
Tanaka, Y., Sato, Y., & Sasaki, T. (2013) · Viruses · doi:10.3390/v5051250 · Cited by 158 · see citing works
Bonomi, L., Ghilardi, L., Arnoldi, E., Tondini, C. A., & Bettini, A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.021 · Cited by 58 · see citing works
Araki, K., Gangappa, S., Dillehay, D. L., Rouse, B. T., Larsen, C. P., & Ahmed, R. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100124 · Cited by 43 · see citing works
LY6E impairs coronavirus fusion and confers immune control of viral diseasePreprint
Pfaender, S., Mar, K. B., Michailidis, E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.05.979260 · Cited by 38 · see citing works
Xu, L., Mao, Y., & Chen, G. (2020) · medRxiv · doi:10.1101/2020.03.30.20047415 · Cited by 35 · see citing works
Pathogenicity of Pandemic H1N1 Influenza A Virus in Immunocompromised Cynomolgus Macaques
Pham, V. L., Nakayama, M., Itoh, Y., Ishigaki, H., Kitano, M., Arikata, M., Ishida, H., Kitagawa, N., Shichinohe, S., Okamatsu, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075910 · Cited by 24 · see citing works
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
IL-6: Relevance for immunopathology of SARS-CoV-2
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.009 · Cited by 340 · see citing works
Tomasoni, D., Italia, L., Adamo, M., Inciardi, R. M., Lombardi, C., Solomon, S. D., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1871 · Cited by 235 · see citing works
Li, X.-L., Gong, N.-Q., Tian, F.-L., Zhang, S., Zhang, Y., Wang, Y., Qing, G.-C., Wang, Y.-C., Li, F.-Z., Xu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01084-4 · Cited by 69 · see citing works
SARS-CoV-2 and cancer: Are they really partners in crime?
van Dam, P. A., Huizing, M. T., Mestach, G., Dierckxsens, S., Tjalma, W. A. A., Trinh, X. B., Papadimitriou, K., Altıntaş, S., Vermorken, J. B., Vulsteke, C., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102068 · Cited by 65 · see citing works
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 65 · see citing works
Ali, S. A., Singh, G., & Datusalia, A. K. (2021) · Phytotherapy Research · doi:10.1002/ptr.7068 · Cited by 49 · see citing works
Application of lung microphysiological systems to COVID-19 modeling and drug discovery: a review
Sun, A., Hoffman, T., Luu, B. Q., Ashammakhi, N. A., & Li, S. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00136-5 · Cited by 43 · see citing works
Hong, R., Zhao, H., Wang, Y., Chen, Y., Cai, H., Hu, Y., Wei, G., & Huang, H. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01060-5 · Cited by 39 · see citing works
Immunometabolic Status of COVID-19 Cancer Patients
Sica, A., Colombo, M. P., Trama, A., Horn, L., Garassino, M. C., & Torri, V. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2020 · Cited by 35 · see citing works
Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape
Hossain, M. S., Hami, I., Sawrav, M. S. S., Rabbi, M. F., Saha, O., Bahadur, N. M., & Rahaman, M. M. (2020) · Discoveries · doi:10.15190/d.2020.18 · Cited by 27 · see citing works
Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?
Kiselevskiy, M., Shubina, I. Z., Chikileva, I. O., Ситдикова, С. М., Самойленко, И. В., Anisimova, N. Y., Киргизов, К. И., Сулейманова, А. М., Gorbunova, T., & Варфоломеева, С. Р. (2020) · Pharmaceuticals · doi:10.3390/ph13080166 · Cited by 22 · see citing works
Panoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16 · see citing works
Shukla, A. K., Awasthi, K., Usman, K., & Banerjee, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.606 · Cited by 16 · see citing works
Knight, T. E. (2020) · Biopreservation and Biobanking · doi:10.1089/bio.2020.0066 · Cited by 15 · see citing works
Regen med therapeutic opportunities for fighting COVID-19
Atala, A., Henn, A. D., Lundberg, M. S., Ahsan, T., Greenberg, J. M., Krukin, J., Lynum, S., Lutz, C., Cetrulo, K. J., Albanna, M. Z., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0245 · Cited by 14 · see citing works
Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review
Sharma, R., Suravarjhula, L., Banerjee, M., Kumar, G., & Kumar, N. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230220092125 · Cited by 13 · see citing works
COVID-19 in patients with cancer: Risks and precautions
Razavi, A., Hamblin, M. R., & Rezaei, N. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.01.067 · Cited by 12 · see citing works
Li, C., Revote, J., Ramarathinam, S. H., Chung, S. Z., Croft, N. P., Scull, K. E., Huang, Z., Ayala, R., Braun, A., Mifsud, N. A., et al. (2021) · PROTEOMICS · doi:10.1002/pmic.202100036 · Cited by 8 · see citing works
Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic
Fathi, M., Vakili, K. G., Jazi, K., Sadeghi, M. A., Hajiesmaeili, M., Mohamadkhani, A., Rezaei–Tavirani, M., & Tavasol, A. (2021) · Tumori Journal · doi:10.1177/03008916211063939 · Cited by 7 · see citing works
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He, X., & Zeng, X. X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s347297 · Cited by 6 · see citing works
Xiao, Y., Xu, H., Guo, W. Q., Zhao, Y., Luo, Y., Wang, M., He, Z., Ding, Z., Liu, J., Deng, L., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00017-w · Cited by 6 · see citing works
Иванов, Д. О., Petrenko, Y. V., Reznik, V. A., Nasyrov, R. A., Тимченко, В. Н., Павлова, Е. Б., Pavlova, N., Bannova, С. L., Krasnogorskaya, O. L., Kondratyev, G. V., et al. (2022) · Pediatrician (St Petersburg) · doi:10.17816/ped13373-82 · Cited by 3 · see citing works
Sayed, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100425 · Cited by 2 · see citing works
COVID-19 i in the setting of acute lymphoblastic leukaemia (case analysis, resulting in death)
Иванов, Д. О., Petrenko, Y. V., Reznik, V. A., Тимченко, В. Н., Павлова, Е. Б., Chernova, Т. М., Bannova, С. L., Kondratyev, G. V., Krasnogorskaya, O. L., Shakmaeva, M. A., et al. (2022) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2022-14-2-73-82 · Cited by 2 · see citing works
Learning from cancer to address COVID-19
Oláh, E. (2023) · Biologia Futura · doi:10.1007/s42977-023-00156-5 · Cited by 2 · see citing works
Valiev, T. T., Zakharova, E. V., Ignatenko, O. A., Батманова, Н. А., Михайлова, Е. В., Киргизов, К. И., & Варфоломеева, С. Р. (2020) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2020-7-3-104-111 · Cited by 2 · see citing works
Cardiovascular Burden of COVID-19 and the Post-Covid Era
Moscavitch, S. D., Vieira, J. L., & Libby, P. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210001 · Cited by 1 · see citing works
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
Aroldi, A., Chiarle, R., & Gambacorti-Passerini, C. B. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.030 · Cited by 1 · see citing works
Chimeric antigen receptor engineered cells and their clinical application in infectious disease
Chen, Q., Bo, X., Hao, J., Wang, Z., & Li, B. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.129
Pathophysiology and Inflammatory Mechanisms of COVID-19 Headache
Gürses, A. A., Vurallı, D., Aral, A., & Bolay, H. (2023) · Headache · doi:10.1007/978-3-031-26309-5_8
- Authors
- Agarwal, S., & June, C. H.
- Affiliations
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Agarwal, Sangya
- Venue
- Cancer Discovery
- Published
- 2020-06-01
- Volume
- 10
- Issue
- 6
- Pages
- 775-778
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7249633
- OpenAlex
- W3016777798
- Cited by
- 30
- References
- 22
- Citations by year
- 2024: 1 · 2023: 4 · 2022: 4 · 2021: 9 · 2020: 12
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (2R01CA120409)
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- chimeric antigen receptor T cells, COVID-19 pandemic, SARS-CoV-2, hyperinflammation, cytokine release syndrome, macrophage activation, immunopathology, drug repurposing, cancer immunotherapy
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Humans, Immunotherapy, Inflammation, Macrophage Activation, Morbidity, Neoplasms, Pneumonia, Viral, Receptors, Antigen, T-Cell, Cytokines, Coronavirus Infections, Lymphohistiocytosis, Hemophagocytic, Drug Repositioning, Pandemics, Cell- and Tissue-Based Therapy, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
